Targeted oncolytic peptide platform developing AT-101 to treat metastatic ovarian cancer with liver metastases and hepatocellular carcinoma, in late-stage clinical development. Provides safe, effective monotherapy and combination treatment with immuno-oncology agents and chemotherapy for solid tumors with liver metastases.